Skip to main content

Vigil Neuroscience, Inc.

VIGLDelisted
Industry
Biological Products, (No Diagnostic Substances)
SEC CIK
0001827087

Vigil Neuroscience, Inc. was delisted in 2025; its insiders filed their last Form 4 on Aug 7, 2025; 78 institutions reported holding it in 13F filings for Q2 2025, worth $265.8M in total; no superinvestor held it.

Open-market trades, last 90 days

Open-market purchases (P) and sales (S) by Vigil Neuroscience, Inc. insiders, counted by Form 4 filing. Trades with a flagged price and duplicate filings are left out.

Open-market buys
0 filings
Open-market sells
0 filings
Insiders trading
0
Net value
$0
Purchases minus sales

Insider roster

Directors, officers and 10% owners who have filed a Form 4 for Vigil Neuroscience, Inc., current and former, most recent filer first. Last reported holding is the position after the last non-derivative trade in their latest filing.

Insider roster for Vigil Neuroscience, Inc.
NameTitleLast reported holdingLast filingFilings, past year
Atlas Venture Opportunity Fund I, L.P.10% Owner0IndirectAug 7, 20250
Atlas Venture Associates Opportunity I, L.P.10% Owner0IndirectAug 7, 20250
Atlas Venture Associates Opportunity I, LLC10% Owner0IndirectAug 7, 20250
Atlas Venture Fund XII, L.P.10% Owner0IndirectAug 7, 20250
Atlas Venture Associates XII, LLC10% Owner0IndirectAug 7, 20250
Atlas Venture Associates XII, L.P.10% Owner0IndirectAug 7, 20250
Magovcevic-Liebisch IvanaPresident and CEO0Aug 5, 20250
Thistle MaryDirector0Aug 5, 20250
Blanchard Cheryl RDirector0Aug 5, 20250
Booth BruceDirector0IndirectAug 5, 20250
Bruhn Suzanne LouiseDirector0Aug 5, 20250
Ziolkowski Jennifer LynnChief Financial Officer0Aug 5, 20250
Vitorovic StefanDirector0Aug 5, 20250
Koenig GerhardDirector0Aug 5, 20250
Kaufmann PetraChief Medical Officer–Aug 5, 20250
Gray David L. F.Chief Science Officer–Aug 5, 20250
Budd Haeberlein Samantha L.Director0Aug 5, 20250
Verni ChristopherGeneral Counsel4,000May 7, 20240
Silber ChristopherChief Medical Officer–Aug 7, 20230
Thackaberry EvanSVP, Head of Early Development1,500Mar 3, 20230
Papapetropoulos SpyridonChief Medical Officer4,000Nov 22, 20220
Thorp ClayDirector1,556,030IndirectMay 17, 20220
Cormorant Asset Management, LPOther: Former 10% Owner616,786IndirectJan 13, 20220
Chen BihuaOther: Former 10% Owner616,786IndirectJan 13, 20220
Cormorant Global Healthcare Master Fund, LPOther: Former 10% Owner616,786IndirectJan 13, 20220
Cormorant Private Healthcare Fund IV LPOther: Former 10% Owner616,786IndirectJan 13, 20220
Vida Ventures GP III, L.L.C.10% Owner11,536IndirectJan 11, 20220
Vida Ventures III-A, L.P.10% Owner11,536IndirectJan 11, 20220
Vida Ventures III, L.P.10% Owner11,536IndirectJan 11, 20220
Northpond Ventures GP, LLC10% Owner1,382,978IndirectJan 11, 20220
Northpond Ventures, LP10% Owner1,382,978IndirectJan 11, 20220
Rubin Michael P.10% Owner1,382,978IndirectJan 11, 20220
Northpond Ventures II GP, LLC10% Owner1,382,978IndirectJan 11, 20220
Northpond Ventures II, LP10% Owner1,382,978IndirectJan 11, 20220
Amgen Inc10% Owner3,206,281Jan 11, 20220
Alexandria Venture Investments, LLC10% Owner192,973Jan 11, 20220

Insider trades

Each row adds up one type of transaction in one Form 4 filing. Only open-market purchases (P) and sales (S) are shown by default; use the filters to see grants, option exercises and other codes.

Insider trades
Filed (ET)Trade dateFiling delayInsiderTransactionSharesAvg priceValueHolding changeFlags
Dec 19, 2024 (view filing)Dec 19Same dayBudd Haeberlein Samantha L.DirectorPPurchase+12.0K$1.71+$20.5KNew position12.0K after
Dec 19, 2024 (view filing)Dec 19Same dayMagovcevic-Liebisch IvanaPresident and CEOPPurchase+5.00K$1.68+$8.40K+2.3%222.7K after
Dec 18, 2024 (view filing)Dec 18Same dayMagovcevic-Liebisch IvanaPresident and CEOPPurchase+5.00K$1.67+$8.35K+2.4%217.7K after
Dec 5, 2024 (view filing)Dec 5Same dayMagovcevic-Liebisch IvanaPresident and CEOPPurchase+5.00K$2.34+$11.7K+2.4%212.7K after
Nov 20, 2023 (view filing)Nov 20Same dayMagovcevic-Liebisch IvanaPresident and CEOPPurchase+4.00K$3.75+$15.0K+2.0%207.7K after
Nov 22, 2022 (view filing)Nov 184 daysPapapetropoulos SpyridonChief Medical OfficerSSale−300$14.00−$4.20K−7.0%4.00K after
May 17, 2022 (view filing)May 16-171 dayThorp ClayDirectorPPurchase+36.7K$2.85+$104.4K+2.4%1.56M after2 lots
May 6, 2022 (view filing)May 51 dayThackaberry EvanSVP, Head of Early DevelopmentPPurchase+1.50K$4.00+$6.00KNew position1.50K after
May 4, 2022 (view filing)May 31 dayVerni ChristopherGeneral CounselPPurchase+4.00K$3.77+$15.1KNew position4.00K after
May 4, 2022 (view filing)May 2-32 daysMagovcevic-Liebisch IvanaPresident and CEOPPurchase+5.00K$3.68+$18.4K+2.5%203.7K after2 lots
May 4, 2022 (view filing)May 31 dayZiolkowski Jennifer LynnChief Financial OfficerPPurchase+4.00K$3.77+$15.1KNew position4.00K after
May 4, 2022 (view filing)May 31 dayPapapetropoulos SpyridonChief Medical OfficerPPurchase+4.00K$3.40+$13.6KNew position4.00K after
Mar 28, 2022 (view filing)Mar 28Same dayThorp ClayDirectorPPurchase+3.00K$7.20+$21.6KNew position3.00K after
Jan 11, 2022 (view filing)9:18 PM ETJan 11Same dayVida Ventures GP III, L.L.C. and 2 others10% OwnerPPurchase+1.68M$14.00+$23.4MNew position11.5K after2 lotsDuplicate filing
Jan 11, 2022 (view filing)9:15 PM ETJan 11Same dayAtlas Venture Opportunity Fund I, L.P. and 5 others10% OwnerPPurchase+535.0K$14.00+$7.49M+12.5%4.81M afterDuplicate filing
Jan 11, 2022 (view filing)8:18 PM ETJan 11Same dayNorthpond Ventures GP, LLC and 4 others10% OwnerPPurchase+355.0K$14.00+$4.97M+34.5%1.38M after
Jan 11, 2022 (view filing)Jan 11Same dayThorp ClayDirectorPPurchase+265.0K$14.00+$3.71M+21.1%1.52M after
Jan 11, 2022 (view filing)Jan 11Same dayBooth BruceDirectorPPurchase+535.0K$14.00+$7.49M+12.5%4.81M after
Jan 11, 2022 (view filing)Jan 11Same dayVitorovic StefanDirectorPPurchase+1.68M$14.00+$23.4MNew position11.5K after2 lots